ArticleFrontiers in oncology2026
Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allogeneic HCT (allo-HCT). We conducted a retrospective single-center study of adult MM patients who underwent first auto-HCT between 2010 and 2025 and subsequently developed t-HM, analyzing clinical, molecular, cytogenetic features, treatment strategies, and outcomes, with a focus on allo-HCT. Among 519 patients, 23 (4.4%) developed t-HM, including therapy-related acute myeloid leukemia (43%), myelodysplastic syndrome (35%), and B-cell acute lymphoblastic leukemia (17%), with a median latency of 58.7 months after auto-HCT. High-risk genetics were common, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.